Home/Pipeline/Oxy210

Oxy210

Metabolic dysfunction-associated steatohepatitis (MASH)

PreclinicalActive

Key Facts

Indication

Metabolic dysfunction-associated steatohepatitis (MASH)

Phase

Preclinical

Status

Active

Company

MAX BioPharma

About MAX BioPharma

MAX BioPharma is a preclinical biotech leveraging its proprietary Oxysterol Therapeutics® platform to develop small-molecule lipid drugs. Founded on discoveries from UCLA, the company's most advanced candidate, Oxy210, is an oral, antifibrotic/anti-inflammatory agent being developed for MASH. As a private, preclinical-stage company, MAX BioPharma is targeting large, unmet medical needs across fibrosis, inflammation, and infection, but faces the inherent risks of early-stage drug development and platform validation.

View full company profile

Therapeutic Areas

Metabolic Disease Fibrosis Inflammation Infectious Disease Orthopedics

Other Metabolic dysfunction-associated steatohepatitis (MASH) Drugs

Drug	Company	Phase	Status
NGM831 (MK-3655)	NGM Biopharmaceuticals	Phase 2b	Active (Merck-led)
Pegozafermin (BIO89-100)	89bio	Phase 3	Active
Icosabutate	NorthSea Therapeutics	Phase 3	Active
NA-941	Biomed	Phase 2A	Active
PRO-MSH-001	ProdIgY Biotech	Discovery	Active
Undisclosed MASH Program	Syndya Therapeutics	Discovery	Active
Partnered Program	Cellarity	Pre-clinical	Active
Lanifibranor	Hepalys	Phase 1	Active (Japan development program)
IW-601	ImmuneWalk Therapeutics	Preclinical	Active
ION224 (IONIS-DGAT2Rx)	Ionis Pharmaceuticals	Phase 2b	Active
ALG-055009	Aligos Therapeutics	Phase 2	Active
CM-101	Chemomab Therapeutics	Phase 2a	Completed